Author: admin

Chiesi Spain acquires the right of commercialization of Prevencor for treatment of cholesterol and cardiovascular disease prevention within the framework of the agreement reached between Pfizer and Chiesi Spain -the prevalence of hypercholesterolemia in the Spanish population is high and is one of the main factors of cardiovascular risk -Prevencor incorporating a portfolio of Chiesi drugs meana. an injection of turnover exceeding 10% of the current total, reaching the second position in the company’s sales -the agreement reached with Pfizer highlights the commitment of the Chiesi Group by an active policy of partnerships and agreements with companies with which it shares scientific synergiesstrategic and commercial -Chiesi Spain reached a volume of business in 2011 of more than 67 million euros Barcelona, December 2012.- the laboratory pharmacist Chiesi Spain has reached an agreement with Pfizer for marketing Prevencor (atorvastatin), in presentations of 10, 20, 40 and 80 mg. This drug is indicated for the treatment of cholesterol and prevention of cardiovascular disease. The prevalence of hypercholesterolemia in the Spanish population is high. It is one of the major modifiable cardiovascular risk factors since achieving its reduction, achieved decrease the incidence and mortality from ischemic heart disease and cardiovascular disease. Prevencor is indicated as add-on therapy to diet in reducing total cholesterol, LDL cholesterol and apoprotein B triglycerides high in adults, adolescents and children aged 10 years with primary hypercholesterolemia, including...